Digital Pathology Transformation in a Supraregional Germ Cell Tumour Network.
digital
germ cell
pathology
testis
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
25 Nov 2021
25 Nov 2021
Historique:
received:
14
10
2021
revised:
16
11
2021
accepted:
23
11
2021
entrez:
24
12
2021
pubmed:
25
12
2021
medline:
25
12
2021
Statut:
epublish
Résumé
In this article we share our experience of creating a digital pathology (DP) supraregional germ cell tumour service, including full digitisation of the central laboratory. DP infrastructure (Philips) was deployed across our hospital network to allow full central digitisation with partial digitisation of two peripheral sites in the supraregional testis germ cell tumour network. We used a survey-based approach to capture the quantitative and qualitative experiences of the multidisciplinary teams involved. The deployment enabled case sharing for the purposes of diagnostic reporting, second opinion, and supraregional review. DP was seen as a positive step forward for the departments involved, and for the wider germ cell tumour network, and was completed without significant issues. Whilst there were challenges, the transition to DP was regarded as worthwhile, and examples of benefits to patients are already recognised. Pathology networks, including highly specialised services, such as in this study, are ideally suited to be digitised. We highlight many of the benefits but also the challenges that must be overcome for such clinical transformation. Overall, from the survey, the change was seen as universally positive for our service and highlights the importance of engagement of the whole team to achieve success.
Sections du résumé
BACKGROUND
BACKGROUND
In this article we share our experience of creating a digital pathology (DP) supraregional germ cell tumour service, including full digitisation of the central laboratory.
METHODS
METHODS
DP infrastructure (Philips) was deployed across our hospital network to allow full central digitisation with partial digitisation of two peripheral sites in the supraregional testis germ cell tumour network. We used a survey-based approach to capture the quantitative and qualitative experiences of the multidisciplinary teams involved.
RESULTS
RESULTS
The deployment enabled case sharing for the purposes of diagnostic reporting, second opinion, and supraregional review. DP was seen as a positive step forward for the departments involved, and for the wider germ cell tumour network, and was completed without significant issues. Whilst there were challenges, the transition to DP was regarded as worthwhile, and examples of benefits to patients are already recognised.
CONCLUSION
CONCLUSIONS
Pathology networks, including highly specialised services, such as in this study, are ideally suited to be digitised. We highlight many of the benefits but also the challenges that must be overcome for such clinical transformation. Overall, from the survey, the change was seen as universally positive for our service and highlights the importance of engagement of the whole team to achieve success.
Identifiants
pubmed: 34943429
pii: diagnostics11122191
doi: 10.3390/diagnostics11122191
pmc: PMC8700654
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NIHR Oxford Biomedical Research Centre
ID : n/a
Organisme : UK Research and Innovation
ID : 104689
Références
J Clin Pathol. 2020 Apr;73(4):223-227
pubmed: 31597682
Histopathology. 2018 Nov;73(5):784-794
pubmed: 29924891
JCO Clin Cancer Inform. 2019 Jun;3:1-7
pubmed: 31194585
J Clin Pathol. 2017 Dec;70(12):1010-1018
pubmed: 28780514
Lancet Digit Health. 2020 Aug;2(8):e407-e416
pubmed: 33328045
Cancers (Basel). 2021 Mar 16;13(6):
pubmed: 33809521
J Pathol Inform. 2015 Apr 30;6:18
pubmed: 25969793
Histopathology. 2005 Aug;47(2):166-9
pubmed: 16045777
J Pathol Inform. 2019 Dec 03;10:37
pubmed: 31897354
PLoS One. 2021 Feb 25;16(2):e0246958
pubmed: 33630918
Arch Pathol Lab Med. 2017 Jul;141(7):944-959
pubmed: 28440660
J Pathol Inform. 2013 Jun 29;4:15
pubmed: 23858390
J Clin Pathol. 2021 Jul;74(7):448-455
pubmed: 32934103
J Pathol Inform. 2020 Apr 17;11:12
pubmed: 32477618
J Pathol Inform. 2014 Mar 28;5(1):14
pubmed: 24843825
Nat Med. 2019 Aug;25(8):1301-1309
pubmed: 31308507
Mod Pathol. 2019 Jul;32(7):916-928
pubmed: 30778169
J Clin Pathol. 2021 Feb;74(2):129-132
pubmed: 32616541
J Pathol Inform. 2021 Jan 23;12:4
pubmed: 34012708
Arch Pathol Lab Med. 2020 Feb;144(2):221-228
pubmed: 31295015
J Clin Pathol. 2021 Jul;74(7):443-447
pubmed: 32620678
J Pathol. 2019 Oct;249(2):143-150
pubmed: 31144302
Clin Genitourin Cancer. 2017 Feb;15(1):152-156
pubmed: 27324054
Arch Pathol Lab Med. 2021 Sep 1;145(9):1051-1061
pubmed: 33946103
J Clin Pathol. 2019 Feb;72(2):157-164
pubmed: 30518631
J Clin Pathol. 2019 Mar;72(3):198-205
pubmed: 29549217
J Med Internet Res. 2017 Nov 01;19(11):e367
pubmed: 29092808
J Pathol Clin Res. 2021 May;7(3):191-202
pubmed: 33635586